Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 19:37:100541.
doi: 10.1016/j.ensci.2024.100541. eCollection 2024 Dec.

Myasthenia gravis: The evolving therapeutic landscape

Gil I Wolfe  1 , Jonathan E Hanson  1 , Nicholas J Silvestri  1
Affiliations

Myasthenia gravis: The evolving therapeutic landscape

Gil I Wolfe et al. eNeurologicalSci. .

Abstract

Pharmacological options in the management of generalized myasthenia gravis (gMG) have expanded rapidly in the last 7 years. There are now several complement inhibitors and neonatal Fc receptor antagonists on the market in many countries for patient management, following the successful completion of Phase 3 studies. In open-label extensions, these agents have proven to be effective over the longer term extending several years, with benefits such as reduction of corticosteroid requirements being observed. In the communication below, we will briefly summarize recent pharmacologic advancements in the management of gMG and outline how these agents are currently being used and may be used in the future.

Keywords: Complement; Myasthenia gravis; Neonatal Fc receptor; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Gilhus N.E. Myasthenia gravis. N. Engl. J. Med. 2016;375:2570–2581. doi: 10.1056/NEJMra1602678. - DOI - PubMed
    1. Howard J.F., Utsugisawa K., Benatar M., et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3 randomised, double-blind, placebo-controlled multicentre study. Lancet Neurol. 2017;16:976–986. doi: 10.1016/S1474-4422(17)30369-1. - DOI - PubMed
    1. Vu T., Meisel A., Mantegazza R., et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1:1–11. doi: 10.1056/EVIDoa2100066. - DOI - PubMed
    1. Howard J.F., Bresch S., Genge A., et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22:395–406. - PubMed
    1. Muppidi S., Utsugisawa K., Benatar M., et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24. doi: 10.1002/mus.26447. - DOI - PMC - PubMed

LinkOut - more resources